Introduction
Amiodarone (Cordarone | Pacerone | is a predominately Vaughan Williams' class III antiarrhythmic drug introduced in the early 1970s and later approved (1984) in the United States for the treatment of disturbances in the normal heartbeat rhythm generally diagnosed as hemodynamically unstable ventricular tachycardia and ventricular fibrillation. An intravenous formulation was introduced in 1995 for therapy in an urgent care setting.
Amiodarone blocks sodium channels and prolongs the duration of the action potential and refractory period of all cardiac fibers. Following oral administration, amiodarone is slowly and variably absorbed. Studies have shown bioavailability to be between 35 and 65%. Maximum plasma concentrations are attained 3--7 h after single dose with onset of action commonly taking 1-3 weeks. Its large, variable volume of distribution (approximately 60 IJkg) and its high protein binding (96%) pre-clude it from being dialyzable. Amiodarone and, to a greater extent, its metabolite N-desethylamiodarone (DEA) accumulate in adipose tissue and highly perfused organs such as liver, lung, and spleen (1, 2) . The pharmalogical activity of DEA, the major metabolite in humans, is debated in the literature. However, it has been noted that a high concentration of DEA can be correlated with toxicity (3). In chronic therapy, the plasma ratio of metabolite to parent is approximately one. Recent publications have noted altered metabolite concentrations with amiodarone generic substitutions (4) and the dramatic inhibition of amiodarone metabolism by grapefruit juice (5) and other modulators of the CYP3A metabolic pathway (6) . The route of elimination of amiodarone is via hepatic excretion into bile, and some enterohepatic recirculation may occur. Arniodarone has been shown to have a biphasic elimination pattern with an initial half reduction of plasma levels in 2-10 days, followed by a much slower elimination half-life of 26-107 days. This biphasic pattern is likely due to the large volume of distribution, with the drug being rapidly eliminated from highly perfused organs and slowly from less perfused organs, such as adipose tissue, where it has accumulated. DEA has an elimination half-life of approximately 61 days. In absence of a loading dose, steady-state plasma concentrations can take up to 535 days or 180 days with a loading dose. Other potential indications include maintaining the stability of sinus rhythm, secondary prevention to an additional myocardial infarction in primary survivors, and increased survival time in certain therapy-resistant heart failure patients (7) .
Adverse side effects reported include hypersensitivity and interstitial alveolar pneumonitis, in which 10% of cases end in fatality. Other adverse effects include impaired vision; hyper or hypothyroidism, possibly related to the drug containing 37.3% iodine by weight; liver injury; and photosensitivity.
Plasma concentrations below I mg/L are usually therapeutically ineffective, where as levels greater than 2.5 mg/L are not therapeutically necessary. Adverse effects may be more related to duration of treatment than to dose (8) (9) (10) (11) (12) (13) . Because of its narrow therapeutic range (1-3 mg/L) for parent with no established ranges for metabolite and the possibility of serious adverse effects, monitoring of drug concentrations in plasma or serum is useful.
Amiodarone and DEA are generally measured by liquid chromatographic (LC) assays, although an enzyme-linked immunosorbent (ELISA) assay method has been described (14) . In some high-performance liquid chromatography (HPLC) assays, a multistep extraction technique using several solvents is used (15, 16) . Others use protein precipitation methods (17, 18) , whereas still others use solid-phase extraction techniques (19, 20) . Some methods have interference from collection tube peaks (21) or, in the case of the ELISA assay, a cross reactivity with metabolites. The need to measure amiodarone and DEA in plasma or serum samples in a simplified manner prompted the development of an LC assay utilizing solvent extraction. The need for a more rapid method lead to the utilization of Rocket column technology, commonly used in the pharmaceutical industry, but not yet commonly applied to therapeutic management.
Methods
The assay was performed using an HP 1100 LC (Agilent Technologies, Palo Alto, CA) with autosampler, variable wave detector, and a Perkin Elmer Nelson 1022 integrator (Wellesley, MA) for result recording. The detector wavelength was set at 242 nm. The anayltes initially were separated on a 50 mm x 4.6-ram Phenosphere Cyano (Phenomenex, Torrance, CA) 3-p particle column at a flow rate 0.9 mL/min with a backpressure of approximately 95 bar. Comparatively, the analytes were separated using a Plantinum Cyano 33 mm x 7.0-mm Alltech Rocket column (Alltech, Deerfield, IL) with 3 p 100 A packing at a flow rate of 3.0 mL/min, with a back pressure of approximately 51 bar. The mobile phase consisted of acetonitrile/ methanol/0.05M ammonium acetate at 40:56:3, respectively, and was recycled for up to seven days without chromatogram deterioration. HPLC-grade acetonitrile and methanol were purchased from Fisher Scientific (Hampton, NH). The mobile phase was filtered and degassed prior to use through a 0.45-p nylon membrane under vacuum. The internal standard (IS), L8040 [2 ethyl-3-(3,5-dibromo-4-di-n-propylaminopropoxybenzoyl)benzothiophene], amiodarone, and DEA drug stocks were obtained from Sanofi Recherche (Paris, France). The primary stock solutions (100 mg/mL) of amiodarone, DEA, and IS were prepared in methanol. Drug-free plasma was obtained by filtering blood bank plasma though C-18 filters. Filtered plasma calibrators containing both amiodarone and DEA in equal concentrations were prepared over the concentration range of 0.3-6.0 mg/L. The working IS was diluted to a 50-ng/pL concentration in methanol/saline, mixed in a 1:1 ratio.
Samples were prepared by transferring 0.25 mL of patient plasma or serum, plasma positive control, plasma negative control (blank), and calibrators to respective microcentrifuge tubes. Then, 20 pL of the working IS was added to each tube, followed by 0.2 mL of 1M sodium phosphate monobasic (pH 4.5). The tubes were mixed by vortex, then 0.5 mL of HPLC-grade methylt-butyl-ether (Fisher Scientific) was added to each tube. The tubes were then capped, vortex mixed for 30 s, and centrifuged for 5 min at approximately 13,000 rotations per minute (RPM). For analysis, 0.2 mL of the organic phase was transferred to an autosampler vial. Injection volumes utilized were 6 pL for the Phenosphere column and 15 pL for the Rocket column. The integrator then uses a ratio of the peak height of the analyte divided by the peak height of the IS to quantitate the analytes of interest from the four-point calibration curve. Results Figure 1 illustrates an example of a chromatogram from a representative patient sample obtained with both the Phenosphere (1A) and Rocket (1B) columns. The ratios of amiodarone/LS040 and DEA/L8040 were linear between the lower and the upper limits of detection of 0.3 and 6.0 rag/L, respectively, using the criteria of 85-115% of target for accuracy and a coefficient of variation (CV) less than 10% for imprecision. The assay was tested at three concentrations in triplicate on three separate days during one month to study inter-and intrarun variation. This data is summarized in Table I . Recovery was also determined by comparing the average peak height for six extracted plasma samples prepared to contain 1 mg/L concentration with that for unextracted samples of identical concentration. The mean (• SD) percent recoveries on the Phenospere column were 94 • 4.5%, 93 • 5.2%, and 95 • 2.6%, respectively, for amiodarone, DEA, and L8040. An identical study, performed with the Rocket column, produced mean (• SD) percent recoveries of 95 • 3.5%, 94 • 4.2%, and 96 • 1.6%, respectively, for amiodarone, DEA, and L8040. The linear regression of the data obtained with 30 unidentified patient samples using the Rocket column was 1.02x + 0.01 for amiodarone and 0.99x + 0.03 for DEA, as compared to the Phenosphere column. An alternative IS, promazine (Sigma, St. Louis, MO) at 35 mg/mL, was found to be equivalent to the current IS in both chromatographic properties and retention time (data not shown).
No interference or coelution with amiodarone or its metabolite were found with the assay on either column for therapeutic concentrations of drugs found in Table II . No difference was noted in recoveries from plasma and serum (data not shown).
A liquid-liquid extraction was chosen to expand column lifetime for the assay. The assay runs for a total time of 4.5 rain from injection to injection on the Phenosphere column. A substantial decrease to 2.2 rain was achieved when Rocket technology was applied. This technology utilizes a larger column diameter and a shorter length to produce a faster separation. Rocket columns' manufacturing controls the coverage of the bonded phase to the silica backbone. By doing so, a dual-mode separation medium is developed, allowing both polar and nonpolar sites, extending its polar selectivity beyond other reversephase columns. Being built for speed, Rocket columns run more efficiently at higher-than-standards flow rates, but provide excellent peak shape at lower flow rates. Analytes present at low concentrations or numerous peaks closely eluting in the chromatogram may limit this technology (22) .
When compared with a previously published assay (18), our assay shows its merit and cost effectiveness, as shown in Table  III . Potential cost savings lie in the lack of a precolumn, mobile phase stability, and column longevity.
Conclusions
In conclusion, this paper describes a robust assay for the measurement of amiodarone and its metabolite DEA in serum or plasma. The method analysis time was reduced twofold by the application of Rocket column technology, without compromise to clinical utility.
